D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder

American Journal of Psychiatry

Volumn 170, Issue 7, 2013, Pages 751-758

  Hofmann, Stefan G ^a   Smits, Jasper A J ^a   Rosenfield, David ^a   Simon, Naomi ^a   Otto, Michael W ^a   Meuret, Alicia E ^a   Marques, Luana ^a   Fang, Angela ^a   Tart, Candyce ^a   Pollack, Mark H ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; PLACEBO;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LIEBOWITZ SOCIAL ANXIETY SCALE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SOCIAL PHOBIA; THERAPY EFFECT; TREATMENT OUTCOME;

EID: 84881552433     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.12070974     Document Type: Article

References (40)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSMIV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602
2. Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM: Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004; 61: 1005-1013
3. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B: Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003; 71: 1058-1067
4. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF: Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998; 55: 1133-1141
5. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I: Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998; 280: 708-713
6. Blomhoff S, Haug TT, Hellström K, Holme I, Humble M, Madsbu HP, Wold JE: Randomised controlled general practice trial of sertraline, exposure therapy, and combined treatment in generalised social phobia. Br J Psychiatry 2001; 179: 23-30
7. Otto MW, Smits JAJ, Reese HE: Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin Psychol 2005; 12: 72-86
8. Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, Vermes D, Erwin BA, Schmidt AB, Juster HR, Campeas R, Liebowitz MR: A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010; 67: 286-295
9. Falls WA, Miserendino MJD, Davis M: Extinction of fearpotentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci 1992; 12: 854-863
10. Myers KM, Davis M: Behavioral and neural analysis of extinction. Neuron 2002; 36: 567-584
11. Ledgerwood L, Richardson R, Cranney J: Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 2003; 117: 341-349
12. Davis M, Walker DL, Myers KM: Role of the amygdala in fear extinction measured with potentiated startle. Ann N Y Acad Sci 2003; 985: 218-232
13. Walker DL, Ressler KJ, Lu KT, Davis M: Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002; 22: 2343-2351
14. Siegmund A, Golfels F, Finck C, Halisch A, Räth D, Plag J, Ströhle A: D-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res 2011; 45: 1042-1047
15. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R: A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res 2007; 41: 466-471
16. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, Geffken GR, Goodman WK: D-Cycloserine does not enhance exposureresponse prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007; 22: 230-237
17. Berry AC, Rosenfield D, Smits JAJ: Extinction retention predicts improvement in social anxiety symptoms following exposure therapy. Depress Anxiety 2009; 26: 22-27
18. Hofmann SG: Cognitive processes during fear acquisition and extinction in animals and humans: implications for exposure therapy of anxiety disorders. Clin Psychol Rev 2008; 28: 199-210
19. Hofmann SG, Sawyer AT, Asnaani A: D-Cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update. Curr Pharm Des 2012; 18: 5659-5662
20. Hofmann SG, Meuret AE, Smits JAJ, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW: Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63: 298-304
21. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR: A randomized controlled trial of Dcycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63: 544-549
22. de Kleine RA, Hendriks GJ, Kusters WJ, Broekman TG, van Minnen A: A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry 2012; 71: 962-968
23. Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW, Hofmann SG: A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res 2012; 46: 1184-1190
24. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL: Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008; 165: 335-341
25. Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, Micco JA, Sprich S, Wilhelm S, Bengtson M, Geller DA: A preliminary study of D-cycloserine augmentation of cognitivebehavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2010; 68: 1073-1076
26. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB: D-Cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007; 62: 835-838
27. Chasson GS, Buhlmann U, Tolin DF, Rao SR, Reese HE, Rowley T, Welsh KS, Wilhelm S: Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with D-cycloserine. Behav Res Ther 2010; 48: 675-679
28. Hofmann SG, Smits JAJ, Asnaani A, Gutner CA, Otto MW: Cognitive enhancers for anxiety disorders. Pharmacol BiochemBehav 2011; 99: 275-284
29. Liebowitz MR: Social phobia. Mod Probl Pharmacopsychiatry 1987; 22: 141-173
30. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
31. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition. New York, New York State Psychiatric Institute, Biometrics Research, 1995
32. DiNardo PA, Brown TA, Barlow DH: Anxiety Disorders Interview Schedule for DSM-IV: Lifetime Version (ADIS-IV-L). Albany, NY, Graywind Publications Incorporated, 1994
33. Liebowitz MR, Schneier FR, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Klein DF: Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992; 49: 290-300
34. Hofmann SG, Otto MW: Cognitive-Behavior Therapy for Social Anxiety Disorder: Evidence-Based and Disorder-Specific Treatment Techniques. New York, Routledge, 2008
35. Hope DA, Heimberg RG, Turk CL: Managing Social Anxiety: A Cognitive-Behavioral Therapy Approach: Therapist Guide. New York, Oxford University Press, 2006
36. Hofmann SG: Cognitive factors that maintain social anxiety disorder: a comprehensive model and its treatment implications. Cogn Behav Ther 2007; 36: 193-209
37. Hamer RM, Simpson PM: Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry 2009; 166: 639-641
38. Singer JD, Willett JB: Applied Longitudinal Data Analysis. Oxford, UK, Oxford University Press, 2003
39. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH: Efficacy of D-cycloserine for enhancing response to cognitivebehavior therapy for panic disorder. Biol Psychiatry 2010; 67: 365-370
40. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M: Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61: 1136-1144